LEUKEMIA: Circulating cytokines in patients with multiple myeloma inhibit osteoblast differentiation of adipose stem cells

Wherein multiple myeloma (MM) is a plasma cell clonal bone marrow (BM) in the presence of serum and monoclonal proliferation of immune globulin
.
90% of patients have osteolysis-related bone pain and spontaneous fractures as their main symptoms, but they may also be related to anemia, renal failure, hypercalcemia, spinal cord compression, and immunodeficiency

A foreign research team recently discovered that the osteoblast differentiation (MM-ASCs) of ASCs in myeloma patients is defective

In the current work, considering the complex and interrelated effects of different circulating effectors, the research team tested plasma from patients with confirmed myeloma (mm-plasma), plasma from patients with complete remission (cr-plasma), and plasma from healthy donors.
Effect on osteoblast differentiation of ASCs (HD-ASCs) from healthy donors
.
mm-plasma inhibits the osteogenesis of HD-ASCs

Finally, the research team found that in the presence of MM-plasmas or 7 cytokines alone, the expression of CD36 and PPARγ in HD-ASCs was significantly increased, similar to that in MM-ASCs
.

In summary, in addition to the well-known DKK1, specific cytokines in MM plasma can also inhibit the differentiation of MM- and HD-ASCs osteoblasts and tend to differentiate into adipocytes
.
This study provides new insights into the pathogenesis of MM bone lesions, which may lead to the development of new therapeutic strategies, such as neutralizing antibodies and cytokines that target the origin of myeloma osteoblastic defects

Original source:

Kobari, L.